SR 02
Alternative Names: Allogeneic pancreatic endocrine cell clusters - Seraxis; SR-02Latest Information Update: 27 Oct 2025
At a glance
- Originator Seraxis
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Oct 2025 Seraxis withdraws a phase-I/II clinical trials in Type 1 diabetes mellitus in USA (Intraperitoneal) for business reasons (NCT06651515)
- 01 Mar 2025 Phase-I/II clinical trials in Type 1 diabetes mellitus in USA (Intraperitoneal) (NCT06651515)
- 29 Oct 2024 Seraxis has a pending worldwide patent for methods for preparing and use of isolated synthetic replacement endocrine (SRE) cells for treating diabetes